Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMIPAC trial of minimally invasive surgical microwave ablation plus durvalumab, tremelimumab, and gemcitabine for unresectable locally advanced pancreatic cancer
2018-002852-34Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by UZ Leuven. Primary endpoint: Progression-free survival. Started Dec 2019; status: completed.
02
Drugs
durvalumabtremelimumabgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-002852-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002852-34.